L-dopa in the treatment of parkinsonism.
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001161:Arteriosclerosis / Q000150:complications; D001219:Aspartate Aminotransferases / Q000097:blood; D001806:Blood Urea Nitrogen; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D011605:Psychoses, Substance-Induced / Q000209:etiology; D014717:Vertigo / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D004295:Dihydroxyphenylalanine; D001219:Aspartate Aminotransferases